BioSpace News Archive

The global PD-1 and PD-L1 inhibitors market is poised to grow by USD 21.2 billion during 2019-2023, progressing at a CAGR of over 19% during the forecast period.

A probiotic drink could become a promising new weapon in the battle against antibiotic resistant bacteria, after a team of scientists at the University of Birmingham engineered and patented a key genetic element that can tackle the genetic basis of resistance.

Technology being developed aims to bridge the gap between the high cost of treatment for corneal blindness and the unmet medical need in poor communities worldwide.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that it has appointed Novotech as the contract research organization for the Company’s upcoming Phase 2 idiopathic pulmonary fibrosis and chronic cough study for the drug candidate NP-120.

It doesn’t take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, today announced that it is launching a new rapid digital cytology service that digitally connects veterinarians to the largest global network of more than 100 veterinary clinical pathologists and enables them to receive cytology interpretations within 2 hours.

Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders

Tetra Bio Pharma Inc. announced that Health Canada has granted two Drug Identification Numbers for the first over-the-counter products to be marketed under its TERPACAN™ banner..